No Data
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)
Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target
Intra-Cellular Therapies' (NASDAQ:ITCI) Investors Will Be Pleased With Their Fantastic 798% Return Over the Last Five Years
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman